Is It Time for Ocrelizumab Extended Interval Dosing in Relapsing Remitting MS? Evidence from An Italian Multicenter Experience During the COVID-19 Pandemic

In the COVID-19 pandemic era, safety concerns have been raised regarding the risk of severe infection following administration of ocrelizumab (OCR), a B-cell-depleting therapy. We enrolled all relapsing remitting multiple sclerosis (RRMS) patients who received maintenance doses of OCR from January 2...

Descripción completa

Detalles Bibliográficos
Autores principales: Zanghì, Aurora, Avolio, Carlo, Signoriello, Elisabetta, Abbadessa, Gianmarco, Cellerino, Maria, Ferraro, Diana, Messina, Christian, Barone, Stefania, Callari, Graziella, Tsantes, Elena, Sola, Patrizia, Valentino, Paola, Granella, Franco, Patti, Francesco, Lus, Giacomo, Bonavita, Simona, Inglese, Matilde, D’Amico, Emanuele
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9422942/
https://www.ncbi.nlm.nih.gov/pubmed/36036858
http://dx.doi.org/10.1007/s13311-022-01289-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9422942/
https://www.ncbi.nlm.nih.gov/pubmed/36036858
http://dx.doi.org/10.1007/s13311-022-01289-6

Ejemplares similares